纳武利尤单抗联合伊匹木单抗治疗具有免疫原性特征的转移性去势抵抗性前列腺癌:多中心、两队列、II期NEPTUNES研究
NEPTUNES研究是一项开放标签、两队列II期试验,评估纳武利尤单抗联合伊匹木单抗在免疫原性特征阳性(ImS+)的转移性去势抵抗性前列腺癌(mCRPC)患者中的疗效。C1组(纳武利尤单抗1 mg/kg+伊匹木单抗3 mg/kg)复合缓解率(CRR)为40%(14/35),C2组(纳武利尤单抗3 mg/kg+伊匹木单抗1 mg/kg)为25%(9/36);C1组3-4级治疗相关不良事件发生率为63%,C2组为33%。
要点
- ImS+ mCRPC患者中,C1组CRR为40%(14/35),C2组为25%(9/36)。
- C1组3-4级治疗相关不良事件发生率为63%(22/35),C2组为33%(12/36)。
- 错配修复缺陷(MMRD)患者缓解率较高(7/10),高炎症浸润(HII)是前瞻性测试的有前景的预测生物标志物。
核心结论
- 纳武利尤单抗1 mg/kg联合伊匹木单抗3 mg/kg是ImS+经治mCRPC的有效治疗方案。
- 纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg毒性较低但疗效可能较低。
- HII是前列腺癌中有前景的前瞻性测试预测生物标志物,可整合到未来试验中。
研究设计与样本
- 开放标签、两队列、II期试验,纳入ImS+ mCRPC且至少一线治疗进展的患者。
- ImS+定义为:错配修复缺陷(MMRD);DNA损伤修复基因缺失;和/或高炎症浸润(HII)。
- 患者接受4剂纳武利尤单抗1 mg/kg+伊匹木单抗3 mg/kg(C1)或纳武利尤单抗3 mg/kg+伊匹木单抗1 mg/kg(C2),随后纳武利尤单抗480 mg每4周一次,最多10个周期。
- 主要终点为复合缓解率(CRR),通过影像学、生化和循环肿瘤细胞减少评估。
主要发现
- 2018年5月至2022年6月,C1组35例、C2组36例患者开始治疗。
- C1组CRR为14/35(40%,90% CI 26%至55%),C2组为9/36(25%,90% CI 14%至40%)。
- 总体CRR为23/71(32%,90% CI 23%至43%)。
- MMRD患者缓解率为7/10,BRCA2缺失患者为4/8,HII±其他ImS+特征患者为13/30。
- HII不伴其他ImS+特征、DNA修复基因缺失不伴MMRD、MMRD患者的缓解持续时间分别为2.6、17.3和10个月。
临床怎么用
- 作者认为,纳武利尤单抗1 mg/kg联合伊匹木单抗3 mg/kg是ImS+经治mCRPC的积极治疗。
- 作者指出,纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg毒性较低但疗效可能较低。
- 作者认为,HII是有前景的前瞻性测试预测生物标志物,可整合到未来试验中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Efficacy of immune checkpoint inhibitors in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) is limited. The NEPTUNES study evaluated combination nivolumab and ipilimumab in patients with immunogenic signature-positive (ImS+) mCRPC. MATERIALS AND METHODS: This open-label, 2-cohort, phase II trial enrolled patients with ImS+ mCRPC progressing on ≥1 previous line of treatment. ImS+ was defined by (1) mismatch repair deficiency (MMRD); (2) DNA damage repair gene loss; and/or (3) high inflammatory infiltrate (HII). Patients received four doses of nivolumab 1 mg/kg + ipilimumab 3 mg/kg (C1) or nivolumab 3 mg/kg + ipilimumab 1 mg/kg (C2) followed by nivolumab 480 mg once every 4 weeks up to 10 cycles. The primary end point was composite response rate (CRR) assessed radiologically, biochemically, and by reduction of circulating tumor cells. Secondary end points included toxicity, progression-free survival, overall survival, and duration of response. RESULTS: Between May 2018 and June 2022, 35 (C1) and 36 (C2) patients commenced treatment. The CRR in C1 was 14/35 (40%, 90% CI, 26% to 55%) and in C2 was 9/36 (25%, 90% CI, 14% to 40%). The overall CRR was 23/71 (32%, 90% CI, 23% to 43%). Response rates were higher in patients with MMRD (7/10), BRCA2 loss (4/8), and HII ± other ImS+ features (13/30). Duration of response for patients with HII without other ImS+ features, DNA repair gene loss without MMRD, and MMRD was 2.6, 17.3, and 10 months, respectively. Grade 3 to 4 treatment-related adverse events occurred in 22/35 (63%) in C1 and 12/36 (33%) patients in C2. There were no treatment-related deaths. CONCLUSION: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg is an active treatment in ImS+ pretreated mCRPC. Nivolumab 3 mg/kg + ipilimumab 1 mg/kg has less toxicity but may have lower efficacy. HII is a promising prospectively tested predictive biomarker in prostate cancer that could be integrated into future trials.
引用
- Leone G, Wong YNS, Jones RJ, et al. Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study. J Clin Oncol. 2025. PMID: 40720716. doi:10.1200/JCO-24-02637
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。